Aastrom Announces Date of 2011 Annual Meeting of Shareholders
March 25 2011 - 8:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of
expanded, patient specific cellular therapies for the treatment of
severe, chronic cardiovascular diseases, today announced that the
company will hold its 2011 Annual Meeting of Shareholders on June
7, 2011, at 8:30 A.M. (EDT) at the company's headquarters in Ann
Arbor, Michigan. Shareholders of record as of April 11, 2011, are
entitled to notice of and to vote at the meeting. Aastrom plans to
file the definitive proxy statement for the Annual Meeting on April
12, 2011.
The meeting will be webcast live and will also be accessible in
archive until 11:59 P.M. (EDT) on June 21, 2011, beginning two
hours after the meeting. The URL for live and archived access to
the meeting is
http://www.aastrom.com/investor.cfm. Participants should allow
approximately five to ten minutes prior to the meeting start time
to visit the site and download any streaming media software needed
to listen to the webcast. To participate in the live meeting by
telephone, please call (877) 312-5881 and reference Aastrom's
Annual Meeting of Shareholders. If calling from outside the U.S.,
please use the international phone number (253) 237-1173. A replay
of the call will be available 11:30 A.M. (EDT) on June 7, 2011,
until 11:59 P.M. (EDT) on June 21, 2011, by calling (800) 642-1687,
or from outside the U.S. at (706) 645-9291. A podcast will be
available after the live event
at http://www.aastrom.com/events.cfm until 11:59 P.M.
(EDT) on June 21, 2011. The conference ID is 55149669.
About Aastrom Biosciences
Aastrom Biosciences is developing expanded, patient specific
cellular therapies for use in the treatment of severe, chronic
cardiovascular diseases. The company's proprietary cell-processing
technology enables the manufacture of mixed-cell therapies expanded
from a patient's own bone marrow and delivered directly to damaged
tissues. Aastrom has advanced its cell therapies into late-stage
clinical development, including a planned Phase 3 clinical program
for the treatment of patients with critical limb ischemia and two
ongoing Phase 2 clinical trials in patients with dilated
cardiomyopathy. For more information, please visit Aastrom's
website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission. These forward looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media and investor contact
Bill Berry
Berry & Company
212 253-8881
ir@aastrom.com
bberry@berrypr.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024